Disease · MONDO_0005475
migraine with aura
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. migraine with aura. Diseases, record MONDO_0005475. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005475
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SUMATRIPTAN | CHEMBL128 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MELOXICAM | CHEMBL599 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIZATRIPTAN | CHEMBL905 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIZATRIPTAN BENZOATE | CHEMBL1201032 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OCTREOTIDE | CHEMBL1680 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROCHLORPERAZINE | CHEMBL728 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CILOSTAZOL | CHEMBL799 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVCROMAKALIM | CHEMBL100 | Small molecule | Unknown | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| NAPROXEN | CHEMBL154 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets49
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR1B | 5-hydroxytryptamine receptor 1B | 3 | Serotonin 1b (5-HT1b) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3351 | Drugs and targets |
| HTR1D | 5-hydroxytryptamine receptor 1D | 3 | Serotonin 1d (5-HT1d) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3352 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Unknown | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Unknown | https://conductscience.org/library/genes/762 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 1 | Dopamine D2 receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Unknown | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Unknown | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Unknown | https://conductscience.org/library/genes/2557 | Drugs and targets |
1 to 10 of 49
See all 49 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03896009 | Maximizing Outcomes in Treating Acute Migraine | Phase 3 | 1,594 | 2023-08-24 | Migraine | MELOXICAM, RIZATRIPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01004263 | A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) | Phase 3 | 674 | 2012-05-04 | Acute Migraine With or Without Aura in Adolescents | RIZATRIPTAN BENZOATE | Its record names the disease | ClinicalTrials.gov |
| NCT02279082 | DFN-02 Open Label Safety Study in Patients With Acute Migraine | Phase 3 | 167 | 2017-08-28 | Acute Migraine | SUMATRIPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00274170 | Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache | Phase 1/2 | 56 | Migraine Headache | OCTREOTIDE, PROCHLORPERAZINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04905654 | Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura | Not applicable | 35 | Headache, Migraine, Aura | LEVCROMAKALIM | Its record names the disease | ClinicalTrials.gov | |
| NCT00893594 | Efficacy of Sumatriptan With Naprosyn in Migraine With Aura | Not applicable | 30 | Migraine With Aura | NAPROXEN, SUMATRIPTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05565001 | The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. | Not applicable | 20 | Headache, Migraine With Aura, Migraine Without Aura | LEVCROMAKALIM | Its record names the disease | ClinicalTrials.gov | |
| NCT04012047 | Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients | Not applicable | 17 | Headache, Migraine, Aura | LEVCROMAKALIM | Its record names the disease | ClinicalTrials.gov | |
| NCT02253004 | Induction of Migraine Aura With Cilostazol | Early phase 1 | 16 | Migraine With Aura, Stroke | CILOSTAZOL | Its record names the disease | ClinicalTrials.gov | |
| NCT02795351 | Induction of Migraine Aura With Sildenafil | Early phase 1 | 16 | Migraine With Aura | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| AXS-07 vs Placebo: Percentage of Subjects With Absence of Most Bothersome Symptom | 158 of 428 | 51 of 209 | 637 | NCT03896009 | Trial comparisons |
| AXS-07 vs Placebo: Percentage of Subjects Reporting Headache Pain Freedom | 85 of 428 | 14 of 209 | 637 | NCT03896009 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005475
GET https://conductscience.org/api/diseases/v1/MONDO_0005475/targets?page=2